STANDARD TREATMENT WITH BEVACIZUMAB AS TARGETED THERAPY IN CERVICAL CANCER

ISABEL ENRÍQUEZ-ACEVES\(^1\), TATIANA GALICIA-CARMONA\(^2,3\), JAIME A. CORONEL-MARTÍNEZ\(^2,3\), RAQUEL ESPINOSA-ROMERO\(^3\), GERMÁN CALDERILLO-RIÚZ\(^2\), PATRICIA CORTÉS-ESTEBAN\(^4\), AND LUCELY CETINA-PÉREZ\(^2,3\)*

\(^1\)Department of Medical Oncology, Hospital del Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estados (ISSSTE), León, Guanajuato; Departments of \(^2\)Clinical Research and \(^3\)Medical Oncology, Instituto Nacional de Cancerología, Mexico City; \(^4\)Department of Medical Oncology, Centro Médico Nacional 20 de Noviembre, Mexico City, Mexico

ABSTRACT

Metastatic, recurrent, or persistent disease in cervical cancer has a poor prognosis. Historically, this group of patients has had limited treatment options, even with the best cytotoxic treatments (platinum-based chemotherapy [CT] doublets). Therefore, investigating new medications that help improve the patient’s quality of life and survival has been essential. Angiogenesis has been shown to play a critical role in tumor cell growth and survival. Bevacizumab is a recombinant humanized monoclonal G1 immunoglobulin targeted against vascular endothelial growth factor. The combination of CT and bevacizumab is associated with an increase in overall survival as well as in progression-free survival and response rates. (REV INVEST CLIN. [AHEAD OF PRINT])

Key words: Bevacizumab. Cervical. Cancer. Metastatic antiangiogenic.

INTRODUCTION

Cervical cancer (CC) remains a health problem in low- and middle-income countries according to the report issued by GLOBOCAN in 2018\(^1\). In Mexico, 80% of cases are diagnosed at locally advanced stages (IB2 to IVA). The possibility of recurrence is increased according to the initial clinical stage, with recurrence rates in clinical stage IB of 10%, 17% in IIA, 23% in IIB, 42% in IIIA, and 72% in IVA\(^2\). In addition, between 8% and 17% of cases are initially diagnosed in the metastatic stage. Treatment selection in this group of patients will depend on the site of recurrence, whether local, regional, or distant\(^3\).

In metastatic, recurrent, and persistent stages in patients who are not candidates for surgical management and/or radiotherapy, the choice is systemic treatment with platinum-based chemotherapy (CT) doublets. The GOG 204 trial assessed the combination of cisplatin with paclitaxel, vinorelbine, gemcitabine, and topotecan and revealed similar efficacy in terms
of response rates (29%), progression-free survival
(PFS) (5.8 months), and overall survival (OS) (12.9
months), with a tendency for best efficacy in the
cisplatin/paclitaxel group.

Five-year survival in the metastatic stage is 16.5% in
comparison with 91.5% for localized disease. There-
fore, despite the benefits of treatment with CT, there
was a need for novel treatments to improve survival
and quality of life in this group of patients; among the
new biological agents, antiangiogenic therapy has
shown the greatest benefits. The aim of this article is
to analyze the existing publications on the mecha-
nisms behind this therapeutic approach and the ben-
efits and risks of antiangiogenic therapy in advanced
CC patients. To this purpose, the NCBI-PubMed and
Medline databases were used to search for original
articles that reported the results of studies that as-
essed the effect of anti-vascular endothelial growth
factor (anti-VEGF) antibody therapy on response to
treatment, toxicity and side effects, tumor recur-
rence, and OS in CC patients. Other antiangiogenic
therapies were also included in the search. Articles
were reviewed by authors and evaluated using the
GRADE system. Recommendations on the use of an-
tiangiogenic therapy were established according to
the quality of the evidence.

ANTIANGIOGENIC THERAPY IN CC

The main cause of CC is human papillomavirus (HPV)
latent infection. HPV pathogenic activity hinges on
the presence of the E6 and E7 proteins: E6 promotes
p53 degradation, while E7 inactivates the retinoblas-
toma protein. p53 degradation could be responsible
for angiogenesis activation through the production of
VEGF and downregulation of thrombospondin-1 – a
potent angiogenesis inhibitor. Angiogenesis has
a critical function in tumor cell growth and survival,
while VEGF plays a highly important role in its con-
trol, in tumor growth, and in the development of
metastasis.

Some studies have demonstrated the importance of
angiogenesis in premalignant lesions of the cervix,
with an association between microvessel density
and the grade of cervical intraepithelial neoplasia.
Cervical samples with high vascularization have been
associated with worse survival rates in comparison
with poorly vascularized samples (5-year survival of
50% vs. 65%). Furthermore, high levels of VEGF have
been associated with CC advanced stages, higher risk
of metastasis, and worse PFS and OS data.

BEVACIZUMAB IN CC

Bevacizumab is a recombinant humanized monoclonal
G1 immunoglobulin antibody targeted against VEGF
(anti-VEGF), clinically developed for various oncologi-
cal entities. A retrospective study of six heavily pre-
treated CC patients assessed the use of bevacizumab
in combination with 5-fluorouracil or capecitabine.
Clinical benefit was observed in 67% of patients: one
complete response (CR), 17%, one partial response
(PR), 17%, and two patients with stable disease (SD),
33%, with a mean time to progression of 4.3 months.
In addition, the combination was well tolerated, with
anemia being the most common toxic effect. Grade
3 anemia occurred in 17% of patients, Grade 2 in
33%, and Grade 1 in 50%.

Bevacizumab has been assessed in Phase II studies.
One of them analyzed its efficacy and tolerability in
46 patients with recurrent CC. PR was achieved in
10.9% of patients and PFS in 23.9%, for a minimum of
6 months. Mean response duration was 6.21 months,
PFS was 3.4 months (95% CI: 2.53-4.53), and OS 7.29
months (95% CI: 6.11-10.41 months). Among the
main Grade 3 or 4, adverse events (AEs) caused by
bevacizumab, hypertension, pain, and thromboembo-
lism, and other events of hematological, gastrointes-
tinal, genitourinary, and renal origin were reported.

Another Phase II trial evaluated the combination of
CT with topotecan and cisplatin plus bevacizumab
in the treatment of recurrent or persistent carcinoma
of the cervix. Twenty-six patients were evaluated,
one of whom achieved CR and 8 PR, with a mean
response duration of 4.4 months, and 10 patients
had SD with a duration of 2.2 months. The proba-
bility of PFS at 6 months was 59% (80% CI: 46-70%),
and for the set of patients, mean PFS was 7.1 months
(80% CI: 4.7-10.1 months) and mean OS was
13.2 months (80% IC: 8.0-15.4 months). Treat-
ment delay of at least one cycle due to toxicity was
recorded in 59% of patients, while 78% had to be
hospitalized to manage toxicity. Reported hematologic AEs (Grades 3-4) included thrombocytopenia (82%), leukopenia (74%), anemia (63%), and neutropenia (56%). Red blood cell transfusion was required by 78% of patients and platelet transfusion by 30%. Other non-hematologic Grades 3-4 toxicities were metabolic abnormalities (44%), pain (33%), and genitourinary or renal complications (30%). This study showed that the combination of topotecan plus cisplatin with bevacizumab is active but highly toxic.

These studies set the standard for conducting the GOG 240 Phase III trial that, in 2014, led to the approval of bevacizumab by the U.S. Food and Drug Administration for the treatment of advanced CC. The study assessed bevacizumab effectiveness with a combination of CT in patients with recurrent, persistent, or metastatic CC. Four-hundred and fifty-two patients were randomized to receive CT with or without bevacizumab (15 mg/kg day 1). CT consisted of 21-day cycles with cisplatin (50 mg/m² day 1) plus paclitaxel (135 or 175 mg/m² day 1) or topotecan (0.75 mg/m² days 1-3) plus paclitaxel (175 mg/m² day 1). The study data showed that the addition of bevacizumab to CT was associated with an increase in OS (17.0 vs. 13.3 months; HR: 0.71; 95% CI: 0.54-0.95; p = 0.004) and in response rates (48% vs. 36%; p = 0.008) in comparison with CT alone. Bevacizumab was also associated with an increased incidence of AEs, which included Grade ≥2 hypertension (25% vs. 2%), Grade ≥3 thromboembolic events (8% vs. 1%),和 Grade ≥3 gastrointestinal fistulae (3% vs. 0%). There was no quality of life deterioration according to the Functional Assessment of Cancer Therapy-Trial Outcome Index questionnaire for CC, which was applied to patients from cycle 1 through cycle 9 (98.75% CI: –4.1-1.7; p = 0.30)³³.

In the GOG 240 final analysis, the benefit was still a greater OS in patients treated with CT plus bevacizumab in comparison with CT alone (16.8 vs. 13.3 months; HR: 0.77; 95% CI: 0.62-0.95; p = 0.0068). When analyzing by CT, bevacizumab was observed to be able to increase OS only when added to cisplatin plus paclitaxel (17.5 vs. 15.0 months), while there was no difference when added to topotecan plus paclitaxel (16.2 vs. 12.0 months). OS in patients who had not previously received pelvic radiotherapy was higher in the group treated with bevacizumab in comparison with the group treated with CT alone (24.5 vs. 16.8 months), although the differences were not significant (HR: 0.64; 95% CI: 0.37-1.10; p = 0.11). Post-progression OS also did not show significant differences between treatments (8.4 vs. 7.1 months; HR: 0.83; 95% CI: 0.66-1.05; p = 0.06). PFS final data also revealed that adding bevacizumab to CT decreased the risk of progression by approximately 32% in comparison with CT alone (8.2 vs. 6.0 months; HR: 0.68; 95% CI: 0.56-0.84; p = 0.0002). The overall response rate (ORR) was 49% in patients treated with CT plus bevacizumab and 36% for CT alone (p = 0.003), 50% and 46% in patients treated with cisplatin plus paclitaxel with and without bevacizumab, respectively, and 48% and 25% for those who received topotecan plus paclitaxel with and without bevacizumab (p = 0.0004). The most commonly reported AEs were the development of fistulas. The incidence of fistulas of any grade was 15% in patients treated with CT plus bevacizumab versus 1% in those treated with CT alone and Grade 3 fistulas, 6% and <1%, respectively¹⁴.

The incorporation of bevacizumab to the treatment of recurrent, persistent, or metastatic CC represents a huge advance since it shows a survival benefit; however, we lack a biomarker to define which group of patients are candidates for treatment with bevacizumab.

The original impetus to study poor prognosis markers in advanced CC was to identify a priori patients who were unlikely to respond to conventional cytotoxic therapy in an effort to avoid the administration of futile treatment¹⁵. The Moore criteria were identified in the platinum or cytotoxic era when antiangiogenic agents were not yet used in randomized clinical trials in patients with CC¹⁶-¹⁸.

The application of the Moore criteria to the entire GOG-240 study population had the purpose of prospectively analyze previously identified clinical prognostic factors, to validate a score using said criteria: performance status, pelvic disease, ethnicity, disease-free interval <1 year, and previous exposure to cisplatin. Risk categories included low risk (0-1 factor), intermediate risk (2-3 factors), and high risk (4-5 factors). The benefit of receiving bevacizumab was observed to be superior in moderate– and high-risk patients, with an increase in OS of up to 5.8 months¹⁹,²₀. A retrospective study assessed the eligibility of patients with recurrent and
metastatic CC with a follow-up of more than 10 years and found that the main reasons for exclusion from treatment were transvaginal active bleeding and poor renal function21.

The combination of carboplatin and paclitaxel plus bevacizumab in metastatic disease can be considered an alternative treatment option in patients who are not candidates for cisplatin, which is evidence provided by the Japanese study that assessed carboplatin non-inferiority versus cisplatin22.

The preliminary report of the CECILIA open-label Phase II study, which is assessing the efficacy and safety of the combination with carboplatin area under the curve 5 every 3 weeks and paclitaxel at 175 mg/m² plus bevacizumab 15 mg/kg every 3 weeks in 150 patients with metastatic, recurrent, or persistent CC, suggests that the combination is safe, with a similar risk of fistulae to that in the GOG 240 trial23.

With these data, the National Comprehensive Cancer Network, the European Society for Medical Oncology (ESMO) and the American Society of Clinical Oncology (ASCO) guidelines recommend the use of bevacizumab combined with CT in patients with CC, in metastatic or recurrent disease with a high degree of recommendation and high quality of evidence24-26.

OTHER ANTIANGIOGENIC AGENTS AND TARGETED THERAPIES IN THE TREATMENT OF CC

Additional targeted strategies include other antiangiogenic agents (pazopanib, lapatinib, sunitinib, or cediranib), which have not been approved for standard management.

Pazopanib is a tyrosine kinase inhibitor (TKI) that inhibits the signal transduction of multiple VEGF receptors, platelet-derived growth factor receptors (PDGFR), and stem cell receptor (c-KIT). Lapatinib is a TKI that inhibits epidermal growth factor receptor (EGFR) and HER2/neu. One study assessed 230 patients with advanced CC, who were randomized to receive pazopanib or lapatinib monotherapy. Pazopanib showed better PFS (18.1 vs. 17.1 weeks; HR: 0.66; 90% CI: 0.45-0.91; p < 0.013) and OS (50.7 vs. 39.1 weeks; HR: 0.67; 90% CI: 0.46-0.99; p = 0.045) than lapatinib27.

Sunitinib is a TKI that inhibits several VEGF receptors, the PDGFR receptor, and c-kit. A Phase II trial with 19 patients showed a 3.5-month PFS (95% CI: 2.6-7 months) with no documented treatment response and high morbidity with 26.3% of cases developing fistulae, which led to rule out sunitinib monotherapy in CC (19). Cediranib is a TKI that inhibits several VEGF receptors. A Phase II study compared cediranib treatment versus placebo in 69 patients with recurrent or metastatic CC. PFS was 35 weeks for cediranib and 30 weeks for placebo (HR: 0.61; 80% CI: 0.41-0.89; p = 0.046), and ORR was 66% and 42%. Cediranib was associated with a higher incidence of Grade 3 or 4 neutropenia than placebo (31% vs. 9%, p = 0.019); in addition, 50% and 34% of patients experienced Grades 2-4 diarrhea and hypertension, respectively, with no impact on OS28.

Another pathway implicated in CC is that of EGFR which, like angiogenesis, plays an important role in CC pathogenesis. EGFR overexpression in CC is considered a factor of poor prognosis in terms of survival and response to CT29. With the above evidence, EGFR blockade was considered to be a potential approach that could be used in the treatment of CC. Pilot and Phase II trials were conducted with EGFR pathway TKI such as erlotinib and gefitinib. As a single agent, erlotinib was shown to be inefficient, while gefitinib, as second- or third-line treatment, showed no objective response in patients with metastatic disease30,31.

Cetuximab and nimotuzumab, which are anti-EGFR antibodies, either alone or in combination with CT, showed discrete activity in small pilot studies or Phase II clinical trials and although these agents were well tolerated, there was no clinical response32,33.

CONCLUSIONS

Angiogenesis is a process proven to be determinant for tumor growth and invasion. Therefore, antiangiogenic therapy with bevacizumab, targeted against VEGF, shows promise to prevent tumor recurrence and the development of advanced disease. The
combination of CT and bevacizumab is the best approach in advanced CC patients, with a demonstrated increase in OS as well as in PFS and response rates.

RECOMMENDATIONS

1. In patients with recurrent, persistent, or metastatic CC, the use of bevacizumab in combination with platinum-based CT is indicated. Quality of evidence: (GRADE) high. Strength of recommendation: strong in favor of its use.

2. In patients with transvaginal active bleeding, poor renal function, and/or poor performance status, the use of bevacizumab may be considered. Quality of evidence: (GRADE) moderate. Strength of recommendation: weak in favor of its use.

3. In patients with recurrent, persistent, or metastatic CC, the use of carboplatin is non-inferior versus cisplatin; therefore, both are options as first line of treatment. Quality of evidence: (GRADE) high. Strength of recommendation: strong in favor of its use.

4. In patients who have previously received cisplatin concomitant with RT, it is preferred to use carboplatin in metastatic disease. Quality of evidence: (GRADE) high. Strength of recommendation: strong in favor of its use.

5. The use of bevacizumab combined with CT in patients with CC, in metastatic or recurrent disease, is recommended. Quality of evidence: (GRADE) high. Strength of recommendation: strong in favor of its use.

REFERENCES


